Children with pre-existing risk factors for diabetes treated with GH have an increased prevalence of diabetes. It is advised to closely monitor blood glucose level during and after GH treatment especially in those children.
Growth hormone (GH) is a diabetogenic : Background hormone. However, there is a lack of post GH treatment follow-up studies to detect possible late development of diabetes.
To determine the long term risk for diabetes in a cohort of Aim:
children treated with recombinant human growth hormone (rhGH) in Israel, using data from the Israeli National Diabetes Register (INDR) for 2014 as a reference.
Methods:
Between the years 1988 and 2009, 2,513 children under the age of nineteen were approved for GH treatment (mean age 9.2±3.7 years at GH approval and mean follow-up duration 12.1±5.3 years after GH approval). Out of these children 76.8% had IGHD (n=1,499; 59.8%) ( Table 1) . The patients were categorized to a low-risk category that included patients treated for isolated GH deficiency (IGHD) and small for Results: In 2014, a total of 23 patients aged 10-29 years were identified with diabetes. Table 2 presents the SPRs of diabetes in GH treated children and young adults compared to the general population. In the low risk category there was no difference in the prevalence of diabetes compared to the general population (SPR 2.05, 95% CI 0.94-3.89). In the high risk category there was a significantly higher prevalence of diabetes (SPR 11.94, .0) compared to the general population. When we excluded the four patients with pre-existing DM who had diabetes before the commencement of GH treatment, the excess SPRs in the high risk category was slightly attenuated. 
